Status:
UNKNOWN
Assessment of HyperQ Signal for Detecting Ischemia During Dobutamine Stress ECG
Lead Sponsor:
BSP Biological Signal Processing Ltd.
Conditions:
Myocardial Ischemia
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The purpose of the study is to verify the ability of the HyperQ signal to detect Dobutamine induced Ischemia. The gold standard for ischemia will be the results of Angiography if performed, or Echocar...
Detailed Description
Subjects referred for Dobutamine Stress Echocardiography who will sign an Informed consent form will go through the test. High resolution ECG from 12 leads will be recorded using BSP's HyperQ system b...
Eligibility Criteria
Inclusion
- Subject referred to dobutamine stress Echocardiography
- Subject signed informed consent
Exclusion
- Subjects with implantable Pacemakers or Defibrillators
- Subjects with Wolff-Parkinson-White Syndrome
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00310622
Start Date
March 1 2006
End Date
February 1 2007
Last Update
March 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiology Department, Shaarey Zedek Hospital
Jerusalem, Israel